Page 9 - Nasdaq Fold News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Amicus Therapeutics (NASDAQ:FOLD – Get Rating) and Q BioMed (OTCMKTS:QBIO – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership. Profitability This table compares Amicus Therapeutics and Q BioMed’s net […]

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) CEO Bradley L. Campbell sold 11,700 shares of the stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $11.21, for a total transaction of $131,157.00. Following the completion of the transaction, the chief executive officer now directly owns […]

Amicus Therapeutics (NASDAQ:FOLD – Get Rating) had its price target increased by Bank of America from $16.00 to $17.00 in a research report report published on Monday morning, The Fly reports. Bank of America currently has a buy rating on the biopharmaceutical company’s stock. Several other brokerages also recently weighed in on FOLD. UBS Group […]

StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD – Get Rating) from a hold rating to a buy rating in a research note published on Monday morning. FOLD has been the topic of several other research reports. BTIG Research boosted their price target on shares of Amicus Therapeutics from $14.00 to $16.00 and gave the company […]

Amicus Therapeutics (NASDAQ:FOLD – Get Rating) had its target price lifted by investment analysts at Bank of America from $16.00 to $17.00 in a research note issued to investors on Monday, The Fly reports. Bank of America‘s price objective would indicate a potential upside of 53.43% from the company’s current price. Several other equities research […]